Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

International journal of immunopathology and pharmacology - 1 Jan 2000

De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M

Abstract excerpt

The choice to include the optimal protease inhibitor (PI) in highly active antiretroviral therapy (HAART) regimens in children with perinatal HIV-1 infection is still under debate. Virologic and immunologic outcomes of three different regimens in an observational paediatric cohort were compared. Data from 12 saquinavir-, 18 nelfinavir-, and 10 lopinavir/ritonavir-treated children were analyzed after 4 and 24...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4 Lymphocyte Count

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Nelfinavir

Share to Pyrimidinones

Share to Ritonavir

Source

Identifiers

PMID: 16388722
DOI: 10.1177/039463200501800416

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.PMID 16388722Read ↗

Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.Semantic proximity Read ↗

Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants.Semantic proximity Read ↗

Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.Semantic proximity Read ↗

Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.Semantic proximity Read ↗

Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.Semantic proximity Read ↗

Lamivudine monotherapy in children and adolescents: The devil is in the detail.Semantic proximity Read ↗

Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.Semantic proximity Read ↗

Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.Semantic proximity Read ↗

Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.Semantic proximity Read ↗

Immune repopulation after HAART in previously untreated HIV-1-infected childrenSemantic proximity Read ↗

Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children.Semantic proximity Read ↗

Treatment interruption for virological failure or as sparing regimen in children with chronic HIV-1 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.